Thursday, July 10, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Off-patent drugs make up 91% of prescriptions, 18% of spending (NYSE:TEVA)

by Euro Times
November 6, 2022
in Markets
Reading Time: 3 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


Roman Didkivskyi/iStock via Getty Images

Generic and biosimilar medicines represented 91% of the 6.4B prescriptions Americans received in 2021 but accounted for only about 18% of medicinal spending, the latest industry report from the trade group Association for Accessible Medicines (AAM) indicates.

Generics and biosimilars are more affordable but highly similar versions of brand-name drugs. While generics are small molecules manufactured from chemicals, biosimilar products are typically larger, more complex compounds synthesized from living systems.

“In fact, the share of spending attributable to brand drugs has risen even as the total number of prescriptions filled by brand drugs has declined,” the authors wrote.

The publication, titled “2022 U.S. Generic & Biosimilar Medicines Savings Report,” is based on pre-expiry brand prices of over 1,200 generic molecules and their annual sales and volume data.

AAM represents leading stakeholders in the market for generic and biosimilars, such as Teva (NYSE:TEVA), Amneal Pharma (AMRX), Dr. Reddy’s (RDY), Sandoz unit of Novartis (NVS), AmerisourceBergen (ABC), Premier Inc. (PINC), Fresenius (FMS) and Amphastar Pharma (AMPH).

Other notable players in the market include Viatris (VTRS), Amgen (AMGN), Pfizer (PFE), Eli Lilly (LLY), Sanofi (SNY) (OTCPK:SNYNF) (GCVRZ), and Organon (OGN)

According to AAM estimates, the off-patent drugs saved more than $373B for the U.S. healthcare system in 2021, and the savings over the past ten years reached $2.6T, with an annual growth of 7-10%, consistently.

The savings estimate for 2021, which implies a $33B increase from 2020 and a $7B contribution from biosimilars, includes $119B and $178B savings for Medicare and commercial health plans, respectively.

Meanwhile, according to the report, new generics and biosimilars saved $93B for the U.S. healthcare system in 2021, despite challenges for their uptake.

“Although these savings are important, they are also less than what is possible. Increasingly, new generics and biosimilars face challenges to adoption due to delays in health plan coverage,” the authors wrote.

The researchers argue that after the market launch of a generic product, it takes about three years for more than half of all Medicare health plans to cover the treatment. Even the coverage for first generics stagnates over time after more than half of private insurers opt to cover such drugs the year after the launch.

“It is critical that employers and policymakers ensure that health plan formularies cover and prioritize lower-cost generics as quickly as possible,” the authors point out.

According to the report, since the first approval in 2015, the FDA greenlighted 39 biosimilars across 11 molecules while 22 products reached the market leading to more than $13B in savings. On the impact of biosimilar competition, the researchers argue that the new products can lower the cost of both the reference product and copycat version.

Further savings are ahead, given the strong biosimilar pipeline. Per the report, more than 95 biosimilars are currently in development, marking approximately 50% increase over the past four years.

The authors also point to the biosimilar launches scheduled for 2023 and 2024 targeted at Humira and Stelara, the blockbuster autoimmune medications developed by AbbVie (ABBV) and Johnson & Johnson (JNJ), respectively.

“The success of these market entrants will be impacted by the degree to which health plans encourage use of the lower-cost biosimilar over the brand,” they added.

Meanwhile, Seeking Alpha contributor Macrotips Trading argues that investors have “overly penalized” AbbVie (ABBV) for the upcoming patent cliff for Humira in the U.S. The author sees the company’s patient support program, Humira Complete, as a tool to defend Humira market share over low-cost biosimilars.



Source link

Tags: DrugsNYSETEVAOffpatentPrescriptionsSpending
Previous Post

TIM top investor Vivendi keen to discuss network plan with govt

Next Post

Twitter is already testing its $8 per month verification plan

Related Posts

Most Fed officials see rate cuts coming, but opinions vary widely on how many, minutes show

Most Fed officials see rate cuts coming, but opinions vary widely on how many, minutes show

by Jeff Cox
July 10, 2025
0

Federal Reserve officers diverged at their June assembly about how aggressively they'd be prepared to chop rates of interest, break...

America’s Achilles’ Heel in the AI Race

America’s Achilles’ Heel in the AI Race

by Ian King
July 10, 2025
0

If you happen to’ve ever watched or performed water polo, you recognize that matches contain two drastically completely different battles....

6 Steps to Creating a Home Inventory — Before It’s Too Late

6 Steps to Creating a Home Inventory — Before It’s Too Late

by B.T. Ballenger
July 9, 2025
0

Studio Romantic / Shutterstock.comPromoting Disclosure: Whenever you purchase one thing by clicking hyperlinks inside this text, we might earn a...

Prime Day 2025, Day One: Crystal’s Top 10 Favorite Deals!!

Prime Day 2025, Day One: Crystal’s Top 10 Favorite Deals!!

by Gretchen
July 9, 2025
0

Fearful you missed a few of the greatest offers from Prime Days? We’ve acquired you coated with this listing! Wow! Prime...

Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect

Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect

by Staff Correspondent
July 9, 2025
0

Johnson & Johnson’s (NYSE: JNJ) enterprise technique for fiscal 2025 is concentrated on lowering the impression of patent expirations on...

How to get started with ‘revenge savings’

How to get started with ‘revenge savings’

by Sharon Epperson
July 8, 2025
0

Individuals are saving extra money — and for some, the change in behavior comes right down to how they really...

Next Post
Twitter is already testing its  per month verification plan

Twitter is already testing its $8 per month verification plan

Starlink adds a daytime data cap of 1 TB for residential users

Starlink adds a daytime data cap of 1 TB for residential users

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Trump Administration Imposes 50% Tariff on Brazilian Imports

Trump Administration Imposes 50% Tariff on Brazilian Imports

July 10, 2025
TCS Q1 Results: Profit rises 6%, margins beat estimates; EBIT flat QoQ

TCS Q1 Results: Profit rises 6%, margins beat estimates; EBIT flat QoQ

July 10, 2025
Eight killed in overnight Sudanese paramilitary attack: Civilian bunker bombed; health workers targeted

Eight killed in overnight Sudanese paramilitary attack: Civilian bunker bombed; health workers targeted

July 10, 2025
NFT Sales Hit .82B in H1 2025 as Market Cools

NFT Sales Hit $2.82B in H1 2025 as Market Cools

July 10, 2025
Why So Many Women Feel Pain During Their C-Sections

Why So Many Women Feel Pain During Their C-Sections

July 10, 2025
Hundreds of migrants moved from Crete to Greek mainland as island struggles with Libya arrivals

Hundreds of migrants moved from Crete to Greek mainland as island struggles with Libya arrivals

July 10, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Trump Administration Imposes 50% Tariff on Brazilian Imports

TCS Q1 Results: Profit rises 6%, margins beat estimates; EBIT flat QoQ

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In